Understanding, Treating, Enhancing Brains

The Spivack Center focuses on discovering the structural, functional and computational aspects of our brains and identifying clinical treatments for brain disorders that profoundly affect human health and well-being from birth to old age. The Center comprises a unique group of basic science and clinical investigators who address these questions in the context of human neurologic, psychiatric and developmental brain disorders, their causes and their treatment.

Located on the Boston University Medical Campus, the Center facilitates interactive, multi-disciplinary, collaborative research that crosses classic institutional boundaries to translate discoveries from science into clinical treatments for brain disorders that profoundly affect human health and well-being from the newborn to the aged.

Spotlight

2019 Jack Spivack Excellence in Neuroscience Awards Announced

Congratulations to Robert Stern, PhD, Christopher Gabel, PhD, Mark. W. Logue, PhD, Valentina Sabino, PhD, Camron D. Bryant, PhD, Chandramouli Chandrasekaran, PhD. More

Recent Events

Visiting Professor Seminar
Identifying the Earliest Phase of Alzheimer’s Disease
COM-Albert-MarilynMarilyn S. Albert, PhD
Professor of Neurology, Johns Hopkins School of Medicine
Director, Johns Hopkins Alzheimer’s Disease Research Center

Dr. Albert’s major research interests are in the area of cognitive change with age, disease-related changes of cognition (with a particular focus on the early diagnosis of Alzheimer’s disease). Her research has focused on the relationship of cognitive change to brain structure and function, as assessed through imaging, cerebrospinal fluid and other biomarkers.
Thursday, Oct. 29, 2015
2-3:15 p.m. Keefer Auditorium

In The News

Researchers Identify Gene Possibly Linked with Methamphetamine Addiction

COM-Bryant_CamronA new study sheds light on the significance of a potential genetic risk factor for drug addiction and possibly other neuropsychiatric disorders. Researchers at Boston University School of Medicine (BUSM) have for the first time identified a gene that is casually associated with the behavioral stimulant response to the drug methamphetamine. More.